BRAF and urothelial carcinoma: Thus, it appears that, within the evolution of the current case, a therapeutic principle targeting a documented oncogenetic metabolic component (the BRAF/MEK signaling pathway) has led to the emergence of a new neoplasm—an aggressive urothelial carcinoma with tendencies for local progression and morphological divergence (appearance of squamous components).